Enikö Kövari1, François R Herrmann, Constantin Bouras, Gabriel Gold. 1. From the Departments of Mental Health and Psychiatry (E.K., C.B.), and Internal Medicine, Rehabilitation and Geriatrics (F.R.H., G.G.), University Hospitals and Medical Faculty of Geneva, Switzerland.
Abstract
OBJECTIVE: To explore cohort effects on age- and Alzheimer disease (AD)-related neuropathologic changes. METHODS: We compared amyloid deposition in autopsied cases aged 65 years and older who died between 1972 and 2006. We included consecutive cases for 1972-1975, 1980, 1985, 1990, 1995, and 2000-2006. We used linear regression models to assess period effects after adjustment for age, cognitive status, and neurofibrillary tangle (NFT) staging. We calculated amyloid/NFT stage ratios to account for possible changes in AD prevalence/severity over time. RESULTS: Mean amyloid stage was significantly related to year of death (p = 0.001) in the total population (1,599 cases, mean age 82 ± 8 years) and decreased 24%, from 1.88 ± 0.89 to 1.57 ± 0.81 (p < 0.0001), in 1,265 individuals without dementia. This decrease was particularly marked in the oldest age groups; people 85 years and older in 2006 had less amyloid deposition compared with those aged 75 to 84 years in 1972. Recent cohorts had lower amyloid deposition. The amyloid/NFT stage ratio decreased from 1.51 ± 0.74 to 0.99 ± 0.56 (p < 0.0001) in cases without dementia and from 0.74 ± 0.13 to 0.56 ± 0.21 (p = 0.0019) in individuals with dementia, confirming that more recent cases had less amyloid despite higher NFT densities. Cohort effects were highly significant (p < 0.0001). CONCLUSION: The strong cohort effect we describe may influence the performance of early amyloid-based AD markers. It also provides preclinical evidence supporting recently described decreases in AD incidence. This trend, if confirmed in community-based studies, may lead to new insights in our understanding of both normal and pathologic brain aging.
OBJECTIVE: To explore cohort effects on age- and Alzheimer disease (AD)-related neuropathologic changes. METHODS: We compared amyloid deposition in autopsied cases aged 65 years and older who died between 1972 and 2006. We included consecutive cases for 1972-1975, 1980, 1985, 1990, 1995, and 2000-2006. We used linear regression models to assess period effects after adjustment for age, cognitive status, and neurofibrillary tangle (NFT) staging. We calculated amyloid/NFT stage ratios to account for possible changes in AD prevalence/severity over time. RESULTS: Mean amyloid stage was significantly related to year of death (p = 0.001) in the total population (1,599 cases, mean age 82 ± 8 years) and decreased 24%, from 1.88 ± 0.89 to 1.57 ± 0.81 (p < 0.0001), in 1,265 individuals without dementia. This decrease was particularly marked in the oldest age groups; people 85 years and older in 2006 had less amyloid deposition compared with those aged 75 to 84 years in 1972. Recent cohorts had lower amyloid deposition. The amyloid/NFT stage ratio decreased from 1.51 ± 0.74 to 0.99 ± 0.56 (p < 0.0001) in cases without dementia and from 0.74 ± 0.13 to 0.56 ± 0.21 (p = 0.0019) in individuals with dementia, confirming that more recent cases had less amyloid despite higher NFT densities. Cohort effects were highly significant (p < 0.0001). CONCLUSION: The strong cohort effect we describe may influence the performance of early amyloid-based AD markers. It also provides preclinical evidence supporting recently described decreases in AD incidence. This trend, if confirmed in community-based studies, may lead to new insights in our understanding of both normal and pathologic brain aging.
Authors: Richard J Caselli; Amylou C Dueck; Dona E C Locke; Leslie C Baxter; Bryan K Woodruff; Yonas E Geda Journal: J Int Neuropsychol Soc Date: 2015-02-09 Impact factor: 2.892
Authors: Jerzy Wegiel; Michael Flory; Izabela Kuchna; Krzysztof Nowicki; Shuang Yong Ma; Jarek Wegiel; Eulalia Badmaev; Wayne P Silverman; Mony de Leon; Barry Reisberg; Thomas Wisniewski Journal: J Neuropathol Exp Neurol Date: 2017-06-01 Impact factor: 3.685
Authors: Claudia L Satizabal; Alexa S Beiser; Vincent Chouraki; Geneviève Chêne; Carole Dufouil; Sudha Seshadri Journal: N Engl J Med Date: 2016-02-11 Impact factor: 91.245
Authors: Roberto Cabeza; Marilyn Albert; Sylvie Belleville; Fergus I M Craik; Audrey Duarte; Cheryl L Grady; Ulman Lindenberger; Lars Nyberg; Denise C Park; Patricia A Reuter-Lorenz; Michael D Rugg; Jason Steffener; M Natasha Rajah Journal: Nat Rev Neurosci Date: 2018-11 Impact factor: 34.870
Authors: Prashanthi Vemuri; David S Knopman; Timothy G Lesnick; Scott A Przybelski; Michelle M Mielke; Jonathan Graff-Radford; Melissa E Murray; Rosebud O Roberts; Maria Vassilaki; Val J Lowe; Mary M Machulda; David T Jones; Ronald C Petersen; Clifford R Jack Journal: JAMA Neurol Date: 2017-06-01 Impact factor: 18.302